Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Other Operating Expenses: 2020-2025

Historic Other Operating Expenses for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $1.6 million.

  • Lyell Immunopharma's Other Operating Expenses rose 117.95% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 66.22%. This contributed to the annual value of $3.3 million for FY2024, which is 18.60% up from last year.
  • Lyell Immunopharma's Other Operating Expenses amounted to $1.6 million in Q3 2025, which was up 249.81% from -$1.1 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Other Operating Expenses registered a high of $1.6 million during Q3 2025, and its lowest value of -$1.1 million during Q2 2025.
  • For the 3-year period, Lyell Immunopharma's Other Operating Expenses averaged around $613,364, with its median value being $641,000 (2023).
  • Per our database at Business Quant, Lyell Immunopharma's Other Operating Expenses soared by 425.11% in 2022 and then crashed by 208.81% in 2025.
  • Quarterly analysis of 5 years shows Lyell Immunopharma's Other Operating Expenses stood at $798,000 in 2021, then surged by 51.63% to $1.2 million in 2022, then crashed by 47.02% to $641,000 in 2023, then fell by 19.97% to $513,000 in 2024, then surged by 117.95% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, -$1.1 million for Q2 2025, and $119,000 during Q1 2025.